Clinical Trial Search

Primary: Number of Subjects With Post-operative Opioid Usage — 42; 58 Participants

Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 1 Participants

Primary: Incidence of Intra-Operative Hemostatic Intervention — 0.0533; 0.0833 Proportion transections w/ intervention

Primary: Incidence of Intra-Operative Hemostatic Interventions — 1.8 Percentage of vessel transections

Primary: Occurrence of Prolonged Air Leaks — 0.0; 5.8; 37.5 percentage of participants

Primary: Postoperative Chest Drainage Volume up to Chest Drain Removal, Average 3 Days. — 550; 580 ml

Primary: Occurrence of Postoperative Air Leaks — 45.8; 67.9; 88.9 percentage of participants

Primary: The Primary Endpoint of This Study Will be VAS Pain Score at 24 Hours — 4.0; 4.5; 3.0 units on a scale

Primary: Peri-operative Mortality at 30 Days — 0.029 proportion of participants

Primary: Hospital Length of Stay — 12.4; 8.4 days

Primary: Mean Pain Score — 4.55; 3.85; 4.30; 3.80 units on a scale

Primary: Freedom From All-cause Reintervention, All-cause Mortality and Major Adverse Events Within 30 Days After Procedure — 84 Participants

Primary: Discharge 2weeks Exercise Capacity — 408.61; 311.94 meter(M) — p=<0.05

Primary: Number of Participants With Adequate Exposure and Access to Oropharyngeal and Hypopharyngeal Head and Neck Lesions — 147; 23 participants

Primary: Number of Participants Requiring Flexible Fiberoptic Bronchoscopy — 25; 7 Participants

Primary: Number of Participants With Fiberoptic Use During Surgeries Requiring Lung Isolation — 42; 5 Participants — p=<0.0001

Primary: Count of Patients With Grade 3 or Higher Adverse Events. — 3 Participants

Primary: 3D RVEF (Baseline) — 44.71; 48.74; 49.11 percentage — p=0.0167

Primary: Proportion of Procedures Completed With Successful Endoscopic Visualization. — 4 participants

Primary: Average Daily In-Hospital Use of Opioids — 40; 45 Oral Morphine Equivalent per Day

Primary: Number of Hospital Days for Required to Treat Complicated Parapneumonic Effusions or Pleural Empyema. — 13; 18.5 days

Primary: Rate of Device and/or Procedure-related Adverse Events — 42.5 percentage of participants

Primary: Exercise Tolerance — 459.7; 341 Seconds

Primary: Safety Measurement — 0; 0; 0; 0 Adverse events

Primary: Accuracy (FTF Decision on Patient Disposition vs. V-visit Decision on Patient Disposition) — 89 percentage of agreement

Primary: Subject is Alive on Original Device, Transplanted, or Explanted for Recovery at 6 Months — 128 Participants — p=0.0003

Primary: Comparing the Inflammatory Markers During the Operation After the Intervention of the Each Group — 33; 35; 39; 42 pg/L — p=0.025

Primary: Freedom From Major Adverse Events (MAE) at Day 30 — 3; 4 Participants

Primary: Quality of Life at 12 Months — 80.97; 84.02 units on a scale

Primary: Number of Participants With Anastomosis Success — 79; 83 Participants — p=0.9727